AR-320 (suvratoxumab)
Pre-emptive treatment for S. aureus pneumonia in ventilated patients
Phase 3Active
Key Facts
Indication
Pre-emptive treatment for S. aureus pneumonia in ventilated patients
Phase
Phase 3
Status
Active
Company
About Aridis Pharmaceuticals
Aridis Pharmaceuticals is a US-based biotech focused on developing first-in-class anti-infectives, primarily monoclonal antibodies, for serious respiratory infections. The company's core technology identifies potent human mAbs from convalescent patients, creating therapies with mechanisms distinct from traditional antibiotics. Its most advanced assets are AR-301 (Phase 3) for ventilator-associated pneumonia and AR-501 (Phase 2a) for cystic fibrosis, positioning it in the high-need antimicrobial resistance (AMR) space. The company is publicly traded but currently limited to trading on the OTC Expert Market.
View full company profile